Idylla CDx MSI Test
Biocartis Us, Inc. · Decision date Aug 15, 2025
What did the FDA approve?
FDA records P250005 as an original PMA application. The recorded decision is approval, dated Aug 15, 2025.
FDA approval order statement
For in vitro diagnostic use. For Prescription Use Only. For use on the Biocartis Idylla System only.The Idylla CDx MSI Test is an in vitro diagnostic test intended for the qualitative detection of a panel of seven monomorphic biomarkers (ACVR2A, BTBD7, DIDO1, MRE11, RYR3, SEC31A and SULF2) for identification of microsatellite instability (MSI) in colorectal cancer (CRC) tissue. The Idylla CDx MSI Test uses formalin-fixed, paraffin embedded (FFPE) tissue sections from patients with CRC, from which nucleic acids are extracted, then analyzed using PCR amplification and subsequent melt-curve analysis. The Idylla CDx MSI Test reports MSI status as either Microsatellite Stable (MSS) or Microsatellite Instability-High (MSI-H) or invalid. The test is intended as a companion diagnostic to identify CRC patients with MSI-H status, who may benefit from treatment with OPDIVO (nivolumab) as a monotherapy and/or treatment with OPDIVO (nivolumab) in combination with YERVOY (ipilimumab).
- Regulatory pathway
- Original PMA
- Clinical specialty
- Medical Genetics
- Decision date
- Aug 15, 2025
Regulatory record facts
- Identifier
- P250005
- Regulatory pathway
- Premarket approval application
- Applicant
- Biocartis Us, Inc.
- Product code
- SFL
- Decision code
- APPR
- Decision date
- Aug 15, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Nucleic Acid Based Assay, Microsatellite Instability.
- Applicant
- Biocartis Us, Inc.
- Product code
- SFL
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P250005 received
Application receipt date recorded by FDA.
P250005 · FDA decision
APPR
Timeline entries are records held by MedtechLedger for P250005. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code SFL
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Promega Corporation | PMA approval | Sep 15, 2026 | FDA | |
| Promega Corporation | PMA approval | Nov 5, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biocartis Us, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Two Pierce Pl., Suite 1510, Itasca, IL, 60174
Sources and methodology
- Original FDA record: P250005
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
